Mithril II GP LP Invests $4.98 Million in Invivyd, Inc. (NASDAQ:IVVD)

Mithril II GP LP bought a new position in Invivyd, Inc. (NASDAQ:IVVD - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 11,241,580 shares of the company's stock, valued at approximately $4,981,000. Invivyd accounts for about 30.9% of Mithril II GP LP's investment portfolio, making the stock its 2nd largest position. Mithril II GP LP owned approximately 9.40% of Invivyd at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Barclays PLC boosted its stake in shares of Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company's stock worth $120,000 after acquiring an additional 75,780 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Invivyd by 644.1% during the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock worth $114,000 after acquiring an additional 222,375 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Invivyd during the 4th quarter worth $74,000. Jane Street Group LLC boosted its stake in shares of Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock worth $52,000 after acquiring an additional 87,358 shares during the last quarter. Finally, Deutsche Bank AG boosted its stake in shares of Invivyd by 35.2% during the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company's stock worth $385,000 after acquiring an additional 227,463 shares during the last quarter. Institutional investors own 70.36% of the company's stock.

Invivyd Stock Up 10.3%

NASDAQ IVVD traded up $0.07 on Friday, reaching $0.78. The company had a trading volume of 1,678,130 shares, compared to its average volume of 4,426,292. The stock has a market capitalization of $93.17 million, a PE ratio of -0.40 and a beta of 0.40. The firm's 50 day moving average price is $0.63 and its 200 day moving average price is $0.75. Invivyd, Inc. has a 12 month low of $0.35 and a 12 month high of $2.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.10). The business had revenue of $11.30 million for the quarter, compared to the consensus estimate of $34.45 million. On average, research analysts expect that Invivyd, Inc. will post -1.64 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on IVVD shares. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Invivyd in a research note on Wednesday, March 26th. D. Boral Capital restated a "buy" rating and set a $9.00 target price on shares of Invivyd in a research note on Friday.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.